GlassScriptPhysician profile
Tina Graham
NPI 1609124635
$4,556.10
in general payments reported to CMS, 2019-2025
40 companies · $886 in 2025
The $886 reported for 2025 was more than what 85% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $120 · 2022: $715 · 2023: $1,479 · 2024: $1,357 · 2025: $886.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,721.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,721.39 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $528.67 | 2022-2025 | |
| Novo Nordisk INC | $499.60 | 2022-2025 | Ozempic, Rybelsus, Wegovy |
| Novartis Pharmaceuticals Corporation | $401.13 | 2021-2025 | |
| Glaxosmithkline, LLC. | $345.23 | 2022-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Lilly USA, LLC | $327.16 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Pfizer INC. | $298.29 | 2022-2025 | |
| Janssen Pharmaceuticals, INC | $246.71 | 2021-2024 | Xarelto |
| Daiichi Sankyo INC. | $174.07 | 2022-2024 | Injectafer |
| Astrazeneca Pharmaceuticals LP | $164.49 | 2023-2025 | Breztri, Farxiga, Airsupra |
| Merck Sharp & Dohme LLC | $128.37 | 2022-2025 | Verquvo, Gardasil 9, Belsomra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $120.15 | 2022-2024 | Jardiance, Tradjenta, Synjardy |
| Bayer Healthcare Pharmaceuticals INC. | $109.60 | 2022-2025 | |
| Amgen INC. | $94.51 | 2022-2025 | Repatha, Evenity, Otezla |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $93.95 | 2023-2024 | Xifaxan |
| Ardelyx, INC. | $82.06 | 2024-2025 | Ibsrela |
Show all 40 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tina Graham listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.